Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with relapsing remitting MS.
Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy.
Patients who had been previously on 2nd line therapies. It was understood that these patients satisfied the above mentioned criteria listed under a. in the past.
This also included patients, who were previously treated with fingolimod (regardless of whether or not they had already been treated within the START study) but discontinued treatment due to medical reasons.
\- or patients with rapidly evolving severe RRMS (e.g. \> 2 relapses with disease progression in one year and \> 1 Gd-enhancing lesion or with a significant increase in T2 lesions compared to a recent MRI).
You may not be if
immunocompromised patients
active infections
pregnant or nursing women, women of childbearing potential unless using 2 reliable forms of contraception
presence of malignancy (other than localized basal cell carcinoma of the skin).
